Kvika banki hf.: Birkir Jóhannsson new CEO of TM
Birkir Jóhannsson has been appointed CEO of TM, Kvika banki‘s subsidiary. Birkir will be replacing Sigurður Viðarsson as he takes up the position of deputy CEO at Kvika.
Birkir has in past years worked as managing director of core operations and digital solutions at VIS Insurance and has substantial work experience within banking, payment solutions and finance. Birkir has previously been employed at Birti Capital Partners, Valitor, Arion bank and Attorneys atHöfðabakki..
Birkir holds a law degree from the University of Iceland and a master’s degree in corporate finance from Reykjavik University. In addition, Birkir has completed a degree in securities trading and is licensed as a district court attorney.
Birkir will be a member of the Kvika group management board.
When the changes, that Kvika banki introduced on 5 December, have been implemented the Kvika group management team will consist of Kvika banki’s management board, the CEO of TM, the CEO of Kvika asset management and the CEO of Kvika Securities in London.
The group management team will subsequently consist of the following members: Marinó Örn Tryggvason (CEO), Sigurður Viðarsson (deputy CEO), Lilja Jensen (General Counsel), Ólöf Jónsdóttir (Managing Director of Commercial Banking), Bjarni Eyvinds (Managing Director of Corporate Banking and Capital Markets), Eiríkur Magnús Jensson (CFO), Anna Rut Ágústsdóttir (Managing Director of Operations and Development), Thomas Skov Jensen (Managing Director of Risk Management), Hannes Frímann Hrólfsson (CEO of Kvika asset management) and Gunnar Sigurðsson (CEO of Kvika Securities in London). Head of Compliance is Erna Heiðrún Jónsdóttir and the Internal Auditor is Ásta Leonhardsdóttir.
Birkir Jónsson, new CEO of TM:
“I am very excited to start my position at TM and get to know the great team of people working for the company. The Icelandic insurance market has been going through a lot of changes during the last few years, coinciding with developments in consumer preference in communication and distribution channels. TM and Kvika are jointly in an ideal market position to take advantage of the market opportunities presented by these changes and I am proud to be a part of that journey.”
Inga Björg Hjaltadóttir, chairman of the Board of TM:
“We are very pleased that Birkir will be joining TM’s strong management team to lead the company’s journey ahead. Birkir’s previous experience is a great fit for carrying out TM’s digitalisation strategy in conjunction with Kvika group’s market leading digital solutions.
At this time, I would also like to thank Sigurður Viðarsson for his work as CEO of TM. Sigurður has successfully led the challenging transformation implemented following the merger of TM and Kvika and it is beneficial to TM that he will have a strong position within the Kvika group as deputy CEO. Sigurður has had a very successful career as CEO of TM over the past 15 years, during which time the company has been a transition leader within the Icelandic insurance market, delivering solid operational results.”
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
ABN AMRO announces EUR 500 million share buyback programme8.2.2023 07:05:00 CET | Press release
ABN AMRO announces EUR 500 million share buyback programme ABN AMRO today announced the start of a share buyback programme under which it plans to repurchase depositary receipts and ordinary shares of ABN AMRO Bank N.V. for a maximum total value of EUR 500 million and for a number of shares not exceeding the authority granted by the general meeting of shareholders on 20 April 2022 (10% of the issued shares). The share buyback programme will commence on 9 February 2023 and is expected to end no later than June 2023. The purpose of the programme is to reduce ABN AMRO’s share capital. ABN AMRO’s CET1 ratio at the end of the fourth quarter of 2022 was 15.2%. The capital required for the announced share buyback programme has been reserved and is already excluded from the year-end capital ratios. The repurchased shares will be cancelled in due course. The ECB has approved the share buyback programme, which will be executed within the limitations of the authority granted by the general meetin
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure8.2.2023 07:00:00 CET | Press release
PRESS RELEASE Data from GLPi animal studies demonstrate safety of second-generation DSRii product (DSR 2.0)Data from Phase 1 studyof DSR 2.0 in Mexico (CHIHUAHUA) andINDiii filing to US FDA expected in Q1 2023Planning to start MOJAVE, a US Phase 1/2a randomized controlled multi-centerstudy of DSR 2.0,in Q2 2023 Ghent, Belgium – 08February 2023– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the successful completion of its GLP animal studies, demonstrating the safety of its second-generation DSR product (DSR 2.0), following chronic exposure. These animal data, together with the data from the Phase 1 CHIHUAHUA study, are intended to support the US IND filing of DSR 2.0. FDA approval of the US IND will enable the Company to start MOJAVE, its randomized, controlled, multi-center Phase 1/2a US study of DSR 2.0, planned for Q2 2023. The GLP studies wer
ABN AMRO reports net profit of EUR 1,876 million for FY2022 and announces share buyback8.2.2023 07:00:00 CET | Press release
ABN AMRO reports net profit of EUR 1,876 million for FY2022 and announces share buyback Highlights of the quarter Strong finish to the year with a net profit of EUR 354 million in Q4, reflecting higher interest rates and low risk costs Good result in 2022, with a net profit of EUR 1,876 million and an ROE of 8.7%; all client units delivered better resultsNII strong as deposit margins continued to benefit from higher interest rates; impact of higher rates expected to gradually level off Underlying costs 2% lower than in Q3; full-year costs 2023 expected around EUR 5.3 billion as inflation and higher investments delay the impact of savings programmes Credit quality remains solid. Impairments in Q4 were EUR 32 million, as additions for individual clients were partly offset by releases from macroeconomic scenariosCapital position remains strong, with a fully-loaded Basel III CET1 ratio of 15.2% and a Basel IV CET1 ratio of around 16% Final dividend of EUR 0.67 per share; EUR 500 million sh
Santhera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolone8.2.2023 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, February 8, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that it has secured a finalreimbursement agreement with the French authorities related to Raxone®(idebenone)for the treatment of Leber's hereditary optic neuropathy (LHON) and sales are expected to resume shortly. In addition, the Company plans to submit a request in France in the near-term for an early access program for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). Since its introduction in 2015, Raxone was available to patients in France for the treatment of LHON and reimbursed under a temporary financing scheme (formerly known as ATU). From August 2021, after the French authorities challenged the temporary pricing and removed Raxone from the list of reimbursed drugs under an ATU, Santhera has supplied LHON patients with Raxone free of charge in order to secure uninterrupted access. Reimbursement discussions have now concluded with
Equinor ASA: Information relating to the proposed cash dividend for fourth quarter 20228.2.2023 06:52:30 CET | Press release
Key information relating to the proposed ordinary cash dividend and extraordinary cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for fourth quarter 2022. Ordinary cash dividend amount: 0.30 Extraordinary cash dividend: 0.60 Declared currency: USD Last day including rights: 10 May 2023 Ex-date: 11 May 2023 Record date: 12 May 2023 Payment date: 25 May 2023 The proposed ordinary cash dividend amount and extraordinary cash dividend is subject to approval by the Annual General Meeting on 10 May 2023. Other information: Ordinary cash dividend and extraordinary cash dividend per share in NOK will be communicated 22 May 2023. This information is published in accordance with the requirements of the Continuing Obligations. This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act